enlicitide decanoate + alendronate

**Enlicitide decanoate + alendronate** is an oral fixed-dose combination of two drugs: enlicitide decanoate, a macrocyclic peptide that acts as a potent oral inhibitor of PCSK9 and is under investigation for lowering LDL-cholesterol; and alendronate (also known as alendronic acid), a nitrogen-containing bisphosphonate widely used to inhibit bone resorption in osteoporosis and related disorders. Enlicitide decanoate inhibits the protein-protein interaction between PCSK9 and the LDL receptor, thus increasing receptor recycling and LDL clearance from plasma. Alendronate inhibits osteoclast function by blocking a key step in the mevalonate pathway essential for osteoclast survival and activity. The combination is being studied primarily for its safety, pharmacokinetic interactions, and combined therapeutic effects in the population at risk for both osteoporosis and hypercholesterolemia, such as older adults.

Other names

alendronic acidenlicitide decanoate + alendronic acid